New Surfactant-Based Dressing Product to Improve Wound Closure Rates of Nonhealing Wounds

A European Multicenter Study Including 1036 Patients

Francesco Paolo Palumbo, MD; Keith G. Harding, CBE, FRCGP, FRCP, FRCS; Franca Abbritti, MD; Sarah Bradbury, MSc, RN; Jürgen Dietmar Cech, MD, MSc; Nicola Ivins, MSc RGN; Dieter Klein, MD5; Gabrielle Menzinger, MD; Frans Meuleneire, CNS; Simone Seratoni, MD; Christoph Zölß, MD; Dieter Mayer, MD, FEBVS, FAPWCA


Wounds. 2016;28(7):233-240. 

In This Article

Abstract and Introduction


Objective. A new surfactant-based biomaterial containing the antimicrobial 1% silver sulfadiazine (SSD) was developed at the University of Virginia (Charlottesville, VA) to improve outcomes for nonhealing wounds. This study's objective was to clinically test the wound care outcomes of the new surfactant-based antimicrobial wound dressing (SAWD) in a multicenter trial.

Methods and Materials. This cohort study enrolled 1036 patients with any nonhealing wound of > 3 months duration not responding to standard-of-care treatments from 10 wound care centers in 7 European countries. The SAWD was used for all wound types at all stages of complexity, healing, and severity. Data collection ranged from 6 months to 2 years and measured the percentage of patients achieving wound closure and time to complete closure.

Results. Of the 1036 patients, 70% achieved wound closure, 24.6% were still in treatment at data collection, and 5.4% had a therapy change. The majority (56%) of these non-healing wounds achieved wound closure within 11 weeks. Patients were treated with the SAWD for 3 weeks to more than 1 year with no complications or adverse effects from long-term SSD antimicrobial use.

Conclusion. Ten centers concluded that the new SAWD provided positive results (improved wound closure rates, reduction of inflammation, pain, and odor), improvements in clinical application (faster and easier dressing change), and improved patient compliance.


Nonhealing wounds are responsible for a significant economic burden and an increase in morbidity and mortality for patients.[1,2] These wounds, along with myriad dressing and medication choices, are the subject of intensive research. In addition, an extensive number of protocols exists for managing these debilitating wounds. Nevertheless, rates of clinical wound closure remain unacceptably low, and the burden of disease is rising.[3]

Physicians and scientists at the University of Virginia (Charlottesville, VA) developed a new surfactant-based biomaterial containing 1% silver sulfadiazine (SSD) to improve outcomes for chronic wounds. The aim of this study was to clinically test the wound care outcomes of the new surfactant-based antimicrobial wound dressing (SAWD) in a multicenter setting.